Asset Details
Do you wish to reserve the book?
Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy
Do you wish to request the book?
Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy
2011
Overview
The impact of controlled administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the risk of acute infectious diseases was studied in healthy newborn infants. In this double-blind, placebo-controlled study, 109 newborn 1-month-old infants were assigned randomly to a probiotic group receiving a BB-12-containing tablet (n 55) or to a control group receiving a control tablet (n 54). Test tablets were administered to the infants twice a day (daily dose of BB-12 10 billion colony-forming units) from the age of 1–2 months to 8 months with a novel slow-release pacifier or a spoon. Breastfeeding habits, pacifier use, dietary habits, medications and all signs and symptoms of acute infections were registered. At the age of 8 months, faecal samples were collected for BB-12 determination (quantitative PCR method). The baseline characteristics of the two groups were similar, as was the duration of exclusive breastfeeding. BB-12 was recovered (detection limit log 5) in the faeces of 62 % of the infants receiving the BB-12 tablet. The daily duration of pacifier sucking was not associated with the occurrence of acute otitis media. No significant differences between the groups were observed in reported gastrointestinal symptoms, otitis media or use of antibiotics. However, the infants receiving BB-12 were reported to have experienced fewer respiratory infections (65 v. 94 %; risk ratio 0·69; 95 % CI 0·53, 0·89; P = 0·014) than the control infants. Controlled administration of BB-12 in early childhood may reduce respiratory infections.
Publisher
Cambridge University Press
Subject
/ Anti-Infective Agents - therapeutic use
/ Babies
/ Bifidobacterium - classification
/ Biological and medical sciences
/ feces
/ Fundamental and applied biological sciences. Psychology
/ Human and Clinical Nutrition
/ Humans
/ infancy
/ Infant
/ Infants
/ neonates
/ Otitis Media - prevention & control
/ Probiotics - therapeutic use
/ quantitative polymerase chain reaction
/ Respiratory Tract Infections
/ Respiratory Tract Infections - prevention & control
/ Vertebrates: anatomy and physiology, studies on body, several organs or systems
